Financial Services

Blood-based biomarkers are emerging in neurodegenerative disease testing, enabling earlier, less invasive detection and monitoring. This analysis maps activity across clinical trials, publications, pharma pipelines, and routine clinical use to benchmark key biomarkers, disease focus areas, and leading industry players driving this shift.

This report provides a summary of oncology genomics testing practices, oncologist perspectives and experiences with test providers, and expected future utilization behaviors. A subscription to this report includes 4 waves of data, collected on a quarterly basis (4 reports total, delivered once a quarter).

The third edition of this report provides an overview of the digital pathology market from 2026 to 2031. The digital pathology market, as defined in this report, is comprised of revenue from instruments and software sold to clinical, academic, biopharma, and CRO customers, along with service revenues generated by CROs and reference labs.

Liquid biopsies (LBx), which, to-date, have been used largely for genomic profiling and therapy selection, are finding new applications throughout the patient journey and within pharma research. To help predict the future state of the market, we have developed an evaluation framework to identify and assess areas of growth within the liquid biopsy market.